Target and Manufacturing of Chimeric Antigen Receptor T cells for T-cell Malignancies--Review.
10.19746/j.cnki.issn.1009-2137.2021.01.048
- Author:
Lei YUAN
1
;
Jing WANG
1
;
Xiao-Yan KE
2
Author Information
1. Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
2. Department of Hematology, Peking University Third Hospital, Beijing 100191, China,E-mail: xykbysy@163.com.
- Publication Type:Review
- MeSH:
Humans;
Immunotherapy;
Immunotherapy, Adoptive;
Receptors, Antigen, T-Cell;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Journal of Experimental Hematology
2021;29(1):288-292
- CountryChina
- Language:Chinese
-
Abstract:
T lymphoid malignancy is a group of highly heterogeneous hematological tumors. Disease recurrence and resistance to therapy are the common causes of failed treatment. Traditional therapy is radiotherapy and chemotherapy, although it has achieved great success. However, many patients still failed to survive following the treatment. With the introduction of monoclonal antibodies, immunotherapy and cellular therapy into clinical practice, the outcome of hematologic malignancies has been significantly improved. In particular, chimeric antigen receptor T cells (CAR-T) showed high efficacy in treating B-cell lymphoma and acute B lymphocytic leukemia and surpassed any previous therapeutic strategies. However, this treatment seldom succeeded in treating T cell malignancies. In this review, the history of CAR-T cells treating T cell malignancies, and the clinical trials, adverse events of previously reported were summarized briefly.
